The Italian Administrative Court upholds the condemnation of two pharmaceutical companies for breaching Article 101 TFEU with regard to the marketing (Roche, Novartis)

By a recent judgment in the case Novartis-Roche/AGCM [1] the Regional Administrative Court of Latium (the Court) has uphold on appeal the decision made by Italian Competition Authority (ICA) in the Roche/Novartis case. The ICA had imposed on Roche and Novartis a fine of Euro 180 million for an anti-competitive practice breaching Article 101 TFEU with regard to the marketing of two drugs, Lucentis and Avantis [2]. The Court rejected all the pleadings of the applicants, confirming the fines imposed by the ICA with the appealed decision. The facts of the case and the decision of the Italian Competition Authority The US pharmaceutical company Genentech developed the Lucentis drug for the treatment of macular degeneration and the Avastin drug to treat cancers of the colon, lung, kidney

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Desogus Law Office (Cagliari)

Quotation

Michele Giannino, The Italian Administrative Court upholds the condemnation of two pharmaceutical companies for breaching Article 101 TFEU with regard to the marketing (Roche, Novartis), 2 December 2014, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 70969

Visites 144

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues